Inhibrx Biosciences Inc.(INBX)

Biotechnology · La Jolla, CA

$95.99+1.43 (+1.51%)

Delayed quote: Oct 6, 2026, 11:04 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:07:09.323Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:07:09.323Z.

Quote observation: 2026-10-06T15:04:59.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,408,287,144
Total debt · period ending 2026-06-30: 5,341,000
Cash · period ending 2026-06-30: 133,344,000
TTM operating EBITDA · period ending 2026-06-30: -125,604,000

FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

INBX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

INBX Competitors' EV/EBITDA Ratio

INBX

Inhibrx Biosciences Inc.

Current

Market Cap

$1.41B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRA

Kailera Therapeutics, Inc.

vs INBX

Market Cap

$1.42B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANAB

AnaptysBio, Inc.

vs INBX

Market Cap

$1.44B

EV/EBITDA Ratio

11.62x

TTM Avg

34.83x

3Y Avg

34.83x

5Y Avg

32.76x

BRVE

Braveheart Bio, Inc.

vs INBX

Market Cap

$1.45B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMER

Omeros Corporation

vs INBX

Market Cap

$1.36B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs INBX

Market Cap

$1.46B

EV/EBITDA Ratio

9.03x

TTM Avg

18.38x

3Y Avg

16.03x

5Y Avg

16.85x

MAZE

Maze Therapeutics, Inc.

vs INBX

Market Cap

$1.46B

EV/EBITDA Ratio

N/A

TTM Avg

5.67x

3Y Avg

5.67x

5Y Avg

5.67x

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs INBX

Market Cap

$1.35B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GHRS

GH Research PLC

vs INBX

Market Cap

$1.48B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CERT

Certara, Inc.

vs INBX

Market Cap

$1.48B

EV/EBITDA Ratio

26.86x

TTM Avg

16.63x

3Y Avg

66.61x

5Y Avg

73.09x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Inhibrx Biosciences Inc. (INBX)	$1.41B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.42B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.44B	11.62x	34.83x	34.83x	32.76x
Braveheart Bio, Inc. (BRVE)vs ›	$1.45B	N/A	N/A	N/A	N/A
Omeros Corporation (OMER)vs ›	$1.36B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.46B	9.03x	18.38x	16.03x	16.85x
Maze Therapeutics, Inc. (MAZE)vs ›	$1.46B	N/A	5.67x	5.67x	5.67x
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.35B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.48B	N/A	N/A	N/A	N/A
Certara, Inc. (CERT)vs ›	$1.48B	26.86x	16.63x	66.61x	73.09x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics